Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 823-920-1 | CAS number: 5341-95-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
- Toxic effect type:
- dose-dependent
Effects on fertility
Description of key information
No study on reproductive toxicity is available with the substance. However, reliable data are available for structurally similar substances. In a five generation study with embedded continuous breeding study no effects on fertility were observed in 4 generations up to the highest concentration tested (24% of butane-1,3-diol (CAS 107-88-0) in diet; 12000 mg/kg bw/day). The pregnancy rate of F1A rats decreased during 5 successive mating cycles, no pups were obtained at the highest concentration of the fifth series of litters (F2E). Therefore, the mid dose group (10% in diet; 5000 mg/kg bw/d) was selected as NOAEL. No effects on fertility were observed in additional studies of lower reliability at comparable dose-levels.
Link to relevant study records
- Endpoint:
- multi-generation reproductive toxicity
- Remarks:
- five generation study with embedded continuous breeding study
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1981
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: publication with some shortcomings in documentation (purity of test substance not stated, exposure duration not clearly stated, no statistical evaluation)
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- five generation study with embedded continuous breeding study
- GLP compliance:
- not specified
- Limit test:
- no
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Age at study initiation: 14-15 weeks
- Housing: individually
- Diet: ad libitum
- Water: ad libitum
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 +/- 2°C
- Photoperiod: 12 hrs dark/12 hrs light
- Route of administration:
- oral: feed
- Details on exposure:
- SEMIPURIFIED DIET
Casein: 20 %
Refined corn oil: 8%
Salt mix: 4%
Vitamin mix: 1%
Corn starch 33.5%
Dextrose: 33.5%
DIET PREPARATION
- test diets were prepared by substituting 1,3-butanediol for equal amounts by weight of corn starch and dextrose
- Details on mating procedure:
- - M/F ratio per cage: one male/ one female
- Length of cohabitation: 7 days
- Proof of pregnancy: vaginal plug referred to as day 0 of pregnancy
- After 7 days of unsuccessful pairing replacement of first male by another male.
- Further matings after two unsuccessful attempts: no
- After successful mating each pregnant female was caged individually. - Analytical verification of doses or concentrations:
- no
- Duration of treatment / exposure:
- F0 rats were treated 4 weeks before the mating period. Female rats of the F0 were fed diets containing 1,3-butanediol throughout the mating, gestation and lactating period. After 11 weeks of feeding, 25 males and 25 females from each dosage group of F1A animals were randomly selected and paired to produce the F2 generation (no further information).
- Frequency of treatment:
- daily
- Details on study schedule:
- At 1-2 weeks after weaning of the first litters (F1A), each female of the F0 generation was mated with a different male and a second series of litters was produced (F1B).
All animals of the F1B generation were discarded at weaning except for ten males per group, which were reared to sexual maturity and used in a dominant lethal test. Pubs of the F1A were reared to maturity. After 11 weeks of feeding, 25 males and 25 females from each dosage group of F1A animals were randomly selected and paired to produce the F2 generation. Five successive mating cycles were achieved with the F1A rats within a period of 77 weeks (F2A, F2B, F2C, F2D, F2E).
The F2B, F2C, F2D and F2E were examined and sacrificed as part of the continuous breeding phase of the study, while the F2A litter was mated to produce the F3A and F3B litters. The F3A litter was used for the cytogenetic portion of the study and was mated to produce the F4A and F4B litter, which are indicated by the chart in the orginal paper to be part of the cytogenicity study.
The pregnant dams of the F2A litters (producing the F3B) were divided in two groups: 1/4 were allowed to give birth normally and 3/4 were used for teratological examination on day 19 of gestation. - Remarks:
- 0, 5, 10 and 24 % nominal in diet, corresponding to 0, 2500, 5000 and 12000 mg/kg bw/day, calculated with food factor 0.05 according to Guidance on Information Requirements R.8
- No. of animals per sex per dose:
- 25 rats per sex per dose group in the F0, F1A, F1B, F2A, F3A
- Control animals:
- yes, plain diet
- Positive control:
- none
- Parental animals: Observations and examinations:
- After 4 weeks of feeding of the F0 the respective diets, blood samples were collected from ten rats per sex per group for determination of alkaline phosphatase, glucose, hematocrit, hemoglobin and total and differential leucocyte counts. Urine analysis of the same animals provided measurements of albumin, glucose, ketones, occult blood, pH, specific gravity and microscopic examination. For F1A rats which survived at least 66 weeks, the gonads and pituitary glands were examined microscopically. During the eleventh week of feeding of F1A animals blood and urine samples were collected from ten rats per sex per group and evaluated as mentioned above.
Body weight: yes
Reproductive performance: yes - Litter observations:
- viability, mean pub weight at day 4 and 21 post partum
- Postmortem examinations (parental animals):
- histopathologic examination of the testes or ovaries and pituitary glands of the F1A
- Reproductive indices:
- fertility (percent matings resulting in pregnancies) and gestation indices (percent pregnancies resulting in litters cast alive)
- Offspring viability indices:
- - percent pubs cast alive that survived to 4 days
- percent pups alive at 4 days that survived to 21 days - Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- not specified
- Food efficiency:
- no effects observed
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- not specified
- Immunological findings:
- not specified
- Organ weight findings including organ / body weight ratios:
- not specified
- Histopathological findings: non-neoplastic:
- not specified
- Histopathological findings: neoplastic:
- not specified
- Other effects:
- not specified
- Reproductive function: oestrous cycle:
- not specified
- Reproductive function: sperm measures:
- not specified
- Reproductive performance:
- no effects observed
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 12 000 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: absence of adverse effects
- Remarks on result:
- other: dose calculated (24% in diet, food factor 0.05 according to Guidance on Information Requirements R.8)
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 12 000 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- other: absence of effects on reproduction
- Remarks on result:
- other: dose calculated (24% in diet, food factor 0.05 according to Guidance on Information Requirements R.8)
- Key result
- Critical effects observed:
- no
- Lowest effective dose / conc.:
- 12 000 mg/kg bw/day (nominal)
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Food consumption and compound intake (if feeding study):
- not specified
- Food efficiency:
- no effects observed
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- not specified
- Immunological findings:
- not specified
- Organ weight findings including organ / body weight ratios:
- not specified
- Gross pathological findings:
- not specified
- Neuropathological findings:
- not specified
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- not specified
- Other effects:
- not specified
- Reproductive function: oestrous cycle:
- not specified
- Reproductive function: sperm measures:
- not specified
- Reproductive performance:
- effects observed, treatment-related
- Key result
- Dose descriptor:
- LOAEL
- Effect level:
- 12 000 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- body weight and weight gain
- Remarks on result:
- other: dose calculated (24% in diet, food factor 0.05 according to Guidance on Information Requirements R.8)
- Key result
- Dose descriptor:
- LOAEL
- Effect level:
- 12 000 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- reproductive performance
- Remarks on result:
- other: dose calculated (24% in diet, food factor 0.05 according to Guidance on Information Requirements R.8)
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 5 000 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- body weight and weight gain
- Remarks on result:
- other: dose calculated (24% in diet, food factor 0.05 according to Guidance on Information Requirements R.8)
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 5 000 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- reproductive performance
- Remarks on result:
- other: dose calculated (24% in diet, food factor 0.05 according to Guidance on Information Requirements R.8)
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 12 000 mg/kg bw/day (nominal)
- System:
- other: unspecific effects
- Organ:
- other: body weight gain
- Treatment related:
- yes
- Dose response relationship:
- yes
- Relevant for humans:
- yes
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 12 000 mg/kg bw/day (nominal)
- System:
- female reproductive system
- Organ:
- other: reduced fertility
- Treatment related:
- yes
- Dose response relationship:
- yes
- Relevant for humans:
- yes
- Clinical signs:
- no effects observed
- Mortality / viability:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- not specified
- Food efficiency:
- no effects observed
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- no effects observed
- Sexual maturation:
- not specified
- Organ weight findings including organ / body weight ratios:
- not specified
- Gross pathological findings:
- not specified
- Histopathological findings:
- not specified
- Behaviour (functional findings):
- not specified
- Developmental immunotoxicity:
- not specified
- Key result
- Dose descriptor:
- NOAEL
- Generation:
- F1
- Effect level:
- 12 000 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no developmental toxicity
- Remarks on result:
- other: maternal dose calculated (24% in diet, food factor 0.05 according to Guidance on Information Requirements R.8)
- Key result
- Critical effects observed:
- no
- Lowest effective dose / conc.:
- 12 000 mg/kg bw/day (nominal)
- System:
- other: no developmental effects observed
- Clinical signs:
- no effects observed
- Mortality / viability:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- not specified
- Food efficiency:
- no effects observed
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- no effects observed
- Sexual maturation:
- not specified
- Organ weight findings including organ / body weight ratios:
- not specified
- Gross pathological findings:
- not specified
- Histopathological findings:
- not specified
- Behaviour (functional findings):
- not examined
- Developmental immunotoxicity:
- not examined
- Key result
- Dose descriptor:
- NOAEL
- Generation:
- other: F2A-F2E
- Effect level:
- 12 000 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no developmental effects
- Remarks on result:
- other: maternal dose calculated (24% in diet, food factor 0.05 according to Guidance on Information Requirements R.8)
- Key result
- Critical effects observed:
- no
- Lowest effective dose / conc.:
- 12 000 mg/kg bw/day (nominal)
- System:
- other: no developmental effects observed
- Key result
- Reproductive effects observed:
- yes
- Lowest effective dose / conc.:
- 12 000 mg/kg bw/day
- Treatment related:
- yes
- Relation to other toxic effects:
- reproductive effects in the absence of other toxic effects
- Dose response relationship:
- yes
- Relevant for humans:
- yes
- Conclusions:
- 1,3-butylene glycol did not influence fertility in a five generation study with an embedded continuous breeding study in concentrations up to 10% in the diet (5000 mg/kg bw/d). In the highest concentration tested (24%, 12000 mg/kg bw/d) no offspring in the fifth litter of the F2 generation were produced.
- Executive summary:
Twenty five animals of both sexes were fed either control diet or diet supplemented with 1,3-butylene glycol at dose levels of 5, 10 or 24% of the diet (2500, 5000 or 12000 mg/kg bw/d). Treatment with the test item had no influence on reproduction and lactation parameters for four of five generations of dams and pups. The pregnancy rate of F1A rats decreased during five successive mating cycles: no pups were obtained at the high-dose level group of the fifth series of litters (F2E generation). Excluding this group, the viability of F2 generation pups revealed no significant differences between litters or between control and test groups. Body weight gains of male rats in all four generations were slightly depressed with an apparent dose relationship. Body weight gain of females was not affected (Hess et al., 1981).
The study indicates that fertility is not impaired through 1,3 -butylene glycol exposure up to 10% in diet (5000 mg/kg bw/d).
Reference
Female animals showed no significant abnormal growth rates. Except the P0-Generation, body weight gains of male rats in all four consecutive generations were slightly depressed with an apparent dose relationship (for details see below). The efficiency of food utilization through 10 weeks of post-wening remained constant for all generations of both sexes and was not affected by 1,3-BD treatment.
CLINICAL STUDIES
Hematology, blood chemistry and urinalysis showed no trend associated with treatment for F0, F1, F2 and F3 generation animals
REPRODUCTIVE PERFORMANCE (PARENTAL ANIMALS)
During five successive mating cycles of F1A rats, a gradual decrease in the pregnancy rate was seen. Both the number of pregnant females and the fertility index appeared to be dose-related for several series of F2 litters, especially F2D and F2E. For the fifth series of litters, no pups were obtained in the highest-dose group. However, the gestation, viability and lactation indexes, as well as the mean pup body weights at 4 and 21 days showed no significant differences between specific litter series or between control and test groups (excluding high-dose animals of the fifth series of litters). No significant treatment-related differences were noted on histopathologic examination of testes or ovaries and pituitary glands as a possible explanation of the observed reproductive failure during the fifth cycle.
For the other three generations of dams and pups, no significant dose-related trends were observed for the reproduction and lactation parameters, as described above.
Female animals showed no significant abnormal growth rates. Body weight gains of adult male rats in four F1 generations were slightly depressed with an apparent dose relationship (for details see bel
ow). The efficiency of food utilization through 10 weeks of post-wening remained constant for all generations of both sexes and was not affected by treatment.
REPRODUCTIVE PERFORMANCE (PARENTAL ANIMALS)
During five successive mating cycles of F1A rats, a gradual decrease in the pregnancy rate was seen
. Both the number of pregnant females and the fertility index appeared to be dose-related for several
series of F2 litters, especially F2D and F2E. For the fifth series of litters, no pups were obtained in t
he highest-dose group. However, the gestation, viability and lactation indexes, as well as the mean
pup body weights at 4 and 21 days showed no significant differences between specific litter series or
between control and test groups (excluding high-dose animals of the fifth series of litters). No signifi
cant treatment-related differences were noted on histopathologic examination of testes or ovaries and
pituitary glands as a possible explanation of the observed reproductive failure during the fifth cycle.
For the other three generations of dams and pups, no significant dose-related trends were observed
for the reproduction and lactation parameters, as described above.
Body weight gain of male rats is presented in the following table:
Generation | Dietary level (%) | Weeks | Mean weight gain (g) |
F0 | 0 | 23 | 153 |
5 | 23 | 149 | |
10 | 23 | 141 | |
24 | 23 | 149 | |
F1A | 0 | 77 | 481 |
5 | 77 | 429 | |
10 | 77 | 410 | |
24 | 77 | 383 | |
F1B | 0 | 11 | 298 |
5 | 11 | 278 | |
10 | 11 | 263 | |
24 | 11 | 257 | |
F2A | 0 | 11 | 305 |
5 | 11 | 282 | |
10 | 11 | 278 | |
24 | 11 | 272 | |
F3A | 0 | 9 | 296 |
5 | 9 | 270 | |
10 | 9 | 263 | |
24 | 9 | 222 |
Effect on fertility: via oral route
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 5 000 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
- Quality of whole database:
- sufficient for evaluation
Effect on fertility: via inhalation route
- Endpoint conclusion:
- no study available
Effect on fertility: via dermal route
- Endpoint conclusion:
- no study available
Additional information
No toxicity data on fertility is available for the target substance. However, adequate and reliable data are reported here for a structural analogue (source substance 1,3 -butanediol). Please also refer to the read-across justification document.
Effects on fertility were investigated in rats which received up to 24% butane-1,3-diol in the diet (12000 mg/kg bw/day). No effects were observed in 4 generations of a five generation study, but the pregnancy rate of F1A rats decreased during 5 successive mating cycles and no pubs were obtained at the highest concentration of the fifth series of litters (2FE). Additionally, in this study a dose dependent influence of the test item on the body weight gain of male rats was observed (Hess et al., 1981). The highest dose (24%, 12000 mg/kg bw/day) was therefore regarded as LOAEL and the mid dose (10% in diet, about 5000 mg/kg bw/d) as NOAEL. In spite of some shortcomings in the documentation, this well planned and performed study was judged to be reliable and was selected as key study for this endpoint.
The findings of the key study are supported by the data from one other multigeneration studies, which did not report an impairment of fertility by butane-1,3-diol concentrations of 24% in diet (2000 mg/kg bw/day; Celanese, 1974). However, due to their incomplete documentation these studies were judged to be of lower reliability.
Taking into account all information available for the source substance butane-1,3-diol, there is only single evidence from the continuous breeding study in rats which revealed adverse effects on fertility in the fifth litter of the F1 in the highest dose group (Hess et al. 1981). As the effects were only observed under extreme conditions (continuous breeding) in the highest dose group -- at a dose which is irrelevant under normal use conditions and far (about ten times) above the limit dose usually used for such kind of studies -- these data are regarded as irrelevant with respect to a possible classification. Therefore, it is concluded that no classification for effects on fertility is required.
Effects on developmental toxicity
Description of key information
No teratogenic effects were observed at doses up to 12000 mg/kg bw/day for the ource substance butane-1,3-diol (CAS 107-88-0). Fetotoxicity was observed at doses of 12000 and 5000 mg/kg bw/day (missing or incomplete ossificated sternebrae). The NOAEL for fetotoxicity was 2500 mg/kg bw/day.
Link to relevant study records
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1981
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- test procedure in accordance with national standard methods with acceptable restrictions
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- Study on developmental toxicity. Publication with some shortcomings in documentation (purity of test substance not stated, no statistical evaluation for the majority of end points).
- GLP compliance:
- not specified
- Limit test:
- no
- Species:
- rat
- Strain:
- Wistar
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Age at study initiation: 14-15 weeks
- Housing: individually
- Diet: ad libitum
- Water: ad libitum
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 +/- 2°C
- Photoperiod: 12 hrs dark/12 hrs light - Route of administration:
- oral: feed
- Details on exposure:
- SEMIPURIFIED DIET
Casein: 20 %
Refined corn oil: 8%
Salt mix: 4%
Vitamin mix: 1%
Corn starch 33.5%
Dextrose: 33.5%
DIET PREPARATION
- test diets were prepared by substituting 1,3-butanediol for equal amounts by weight of corn starch and dextrose - Analytical verification of doses or concentrations:
- no
- Details on mating procedure:
- Investigation of teratogenicity was performed with part of the second litter of the F3 generation of a multigeneration study.
- Duration of treatment / exposure:
- day 0 to day 19 of gestation, additional to exposure of the parental (F2) and former generations (F0 and F1)
- Frequency of treatment:
- daily
- Duration of test:
- Part of multigeneration study
- Dose / conc.:
- 0 mg/kg bw/day (nominal)
- Dose / conc.:
- 2 500 mg/kg bw/day (nominal)
- Remarks:
- 5% nominal in diet, corresponding to 2500 mg/kg bw/day, calculated with food factor 0.05 according to Guidance on Information Requirements R.8
- Dose / conc.:
- 5 000 mg/kg bw/day (nominal)
- Remarks:
- 10% nominal in diet, corresponding to 5000 mg/kg bw/day, calculated with food factor 0.05 according to Guidance on Information Requirements R.8
- Dose / conc.:
- 12 000 mg/kg bw/day (nominal)
- Remarks:
- 24 % nominal in diet, corresponding to 12000 mg/kg bw/day, calculated with food factor 0.05 according to Guidance on Information Requirements R.8
- No. of animals per sex per dose:
- 14-15 females per dose group
- Control animals:
- yes, plain diet
- Maternal examinations:
- - sacrifice at day 19 of gestation
- number of implantations, resorptions, viable and nonviable fetuses - Fetal examinations:
- - data on growth abnormalities, weight and sex of fetuses were recorded
- one third of fetuses were examined for soft tissue abnormalities and remaining fetuses were used for skeletal examinations
- soft tissue examinations: fetuses of each group were fixed in Bouin's solution, sectioned according to the method of Wilson and examined in detail for abnormalities
- skeletal examinations: fetuses were fixed in ethyl alcohol and stained with alizarin red and examined for defects - Statistics:
- Skeletal tissue examinations: evaluated by the approximate chi-square test
- Indices:
- Fertility, gestation, gestation and lactation in remaining pups, not sacrificed for teratological examination
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- not specified
- Food consumption and compound intake (if feeding study):
- not specified
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not specified
- Haematological findings:
- not specified
- Clinical biochemistry findings:
- not specified
- Urinalysis findings:
- not specified
- Behaviour (functional findings):
- not specified
- Immunological findings:
- not specified
- Organ weight findings including organ / body weight ratios:
- not specified
- Gross pathological findings:
- not specified
- Neuropathological findings:
- not specified
- Histopathological findings: neoplastic:
- not specified
- Number of abortions:
- no effects observed
- Pre- and post-implantation loss:
- no effects observed
- Total litter losses by resorption:
- no effects observed
- Early or late resorptions:
- no effects observed
- Dead fetuses:
- no effects observed
- Changes in pregnancy duration:
- no effects observed
- Changes in number of pregnant:
- no effects observed
- Details on maternal toxic effects:
- no effects observed
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 12 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- other: maternal toxicity
- Remarks on result:
- other: dose calculated (24% in diet, food factor 0.05 according to Guidance on Information Requirements R.8)
- Key result
- Abnormalities:
- no effects observed
- Fetal body weight changes:
- no effects observed
- Reduction in number of live offspring:
- no effects observed
- Changes in sex ratio:
- no effects observed
- Changes in litter size and weights:
- no effects observed
- Changes in postnatal survival:
- not examined
- External malformations:
- no effects observed
- Skeletal malformations:
- effects observed, treatment-related
- Visceral malformations:
- no effects observed
- Details on embryotoxic / teratogenic effects:
- Embryotoxic / teratogenic effects:yes
Details on embryotoxic / teratogenic effects:
- viability of pups, number of implantation and resorption sites and the mean fetal weight were unaffected by feeding diets with 1,3-butylene glycol up to 24% (12000 mg/kg bw/d), for details see below
- statistically significant increase of incomplete ossification of sternebrae for the middle and high level fetuses as compared with the control fetuses, and a statistically significant increase of missing sternebrae for high dose fetuses, for details see below - Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 12 000 mg/kg bw/day (nominal)
- Basis for effect level:
- other: teratogenicity
- Remarks on result:
- other: maternal dose calculated (24% in diet, food factor 0.05 according to Guidance on Information Requirements R.8)
- Key result
- Dose descriptor:
- LOAEL
- Effect level:
- 5 000 mg/kg bw/day (nominal)
- Basis for effect level:
- other: fetotoxicity
- Remarks on result:
- other: maternal dose calculated (24% in diet, food factor 0.05 according to Guidance on Information Requirements R.8)
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 2 500 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: fetotoxicity
- Remarks on result:
- other: maternal dose calculated (24% in diet, food factor 0.05 according to Guidance on Information Requirements R.8)
- Key result
- Abnormalities:
- effects observed, treatment-related
- Localisation:
- skeletal: sternum
- Description (incidence and severity):
- missing and incomplete ossification of sternebrae
- Key result
- Developmental effects observed:
- yes
- Lowest effective dose / conc.:
- 5 000 mg/kg bw/day
- Treatment related:
- yes
- Relation to maternal toxicity:
- developmental effects in the absence of maternal toxicity effects
- Dose response relationship:
- yes
- Relevant for humans:
- not specified
- Conclusions:
- No teratogenic effects were seen in rats treated with up to 24% (12000 mg/kg bw/d) 1,3-butylene glycol in the diet. But fetotoxic effects occurred in concentrations at or above 10% (5000 mg/kg bw/d) 1,3-butylene glycol in the diet.
- Executive summary:
Teratogenic effects of 1,3-butylene glycol were investigated as part of a multigeneration study in rats receiving 0, 5, 10 and 24% 1,3-butylene glycol in the diet (0, 2500, 5000, 12000 mg/kg bw/d). No conclusive teratogenic effects were seen in pups of the F3B generation at levels up to 12000 mg/kg bw/d 1,3-butylene glycol in the diet. Incomplete sternebral ossification at mid- and high-dose levels and missing sternebrae at high-dose level were noted, probably indicating slight delayed development of fetal skeletal tissue. The NOAEL for fetotoxicity was 2500 mg/kg bw/d of 1,3-butylene glycol in the diet (Hess et al., 1981).
- Endpoint:
- developmental toxicity
- Remarks:
- WEC - Whole-Embryo Culture Assay
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Study period:
- 1985
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- other: WEC - Whole-Embryo Culture Assay
- Version / remarks:
- The European Centre for the Validation of Alternative Methods (ECVAM), Ispra, Italy: Statement on the Scientific Validity of the Postimplantation Rat Whole-Embryo Culture Assay - an In Vitro Test for Embryotoxicity / 2001
- GLP compliance:
- no
- Limit test:
- yes
- Species:
- rat
- Strain:
- Wistar
- Remarks:
- Albino Wistar rats
- Details on test animals or test system and environmental conditions:
- Albino Wistar rats were supplied by the Animal Resources Centre, Murdoch, W.A. Rats were mated overnight and presence of sperm in the vagina was taken as indication of pregnancy (day 0). Embryos were explanted on day 10.
- Route of administration:
- other: via culture medium (rat post-implantation embryo culture model)
- Vehicle:
- other: culture medium
- Analytical verification of doses or concentrations:
- no
- Duration of treatment / exposure:
- 2 hours
- Frequency of treatment:
- static exposure
- Duration of test:
- 2 hours
- Dose / conc.:
- 25 other: mM
- Control animals:
- yes, concurrent no treatment
- Details on study design:
- Rat embryos were explanted on day 10. Uteri were aseptically removed and the decidua dissected free. The deciduum and underlying trophoblast and parietal yolk sac were carefully removed leaving the visceral yolk sac intact. Culture medium consisted of 70% rat serum, Dulbecco’s modification of Eagles minimal essential medium (EDMEM) to which was added 100 IU/ml benzyl penicillin and 100 µf/ml streptomycin sulphate. The culture medium was equilibrated with gases O2, CO2 and N2. The embryos floated in the medium in 60 ml reagent bottles and rotated on a modified haematological roller. After exposure, embryos were evaluated for their morphological development using a dissecting microscope. The number of somites were counted. Embryos were homogenised by ultrasonication and the protein content measured by the method of Lowry and DNA by the fluorometric method of Hinegardner.
- Fetal examinations:
- Endpoints investigated in post-implantation embryo: embryonic protein, DNA, somite development, gross morphology, or viability.
There was no significant effect on the total embryonic protein, DNA or the number of pairs of somites found in post-implanted embryos exposed to butane-2,3-diol via culture medium at a concentration of 25 mM. Furthermore, there were no alterations in the gross morphology or viability of the embryos observed with a dissecting microscope. No effects were seen on growth and development at up to 25 mM. - Statistics:
- Treatments groups were assessed for statistically significant differences by Students t-test.
- Other effects:
- no effects observed
- Details on embryotoxic / teratogenic effects:
- Endpoints observed in post-implantation embryo: embryonic protein, DNA, somite development, gross morphology, or viability
- Key result
- Dose descriptor:
- NOAEC
- Effect level:
- >= 2 253 ppm (nominal)
- Based on:
- test mat.
- Basis for effect level:
- other: no embryotoxicity observed
- Remarks on result:
- other: 25 mM culture medium concentration (2253 mg/L)
- Key result
- Abnormalities:
- no effects observed
- Key result
- Developmental effects observed:
- no
- Conclusions:
- No effects were observed on embryonic protein, DNA, somite development, gross morphology, or viability in post-implantation embryos after 2 hours of exposure to 25 mM butane-2,3-diol (2253 mg/L).
- Executive summary:
Priscott (1984) investigated the effects of acetaldehyde and 2,3-butanediol on rat embryos developing in vitro. The study used rat post-implantation embryo culture model (WEC - Whole-Embryo Culture Assay). Embryo toxicity of 2,3-butanediol were examined in cultured 10-day Albino Wistar rat embryos over a 2-day period (n=12). After exposure to 25 mM (2253 mg/L) of 2,3-butanediol, no differences in embryonic protein, DNA, somite development, gross morphology and viability were observed. 2,3 -butanediol had no significant effect in any of the examined parameter at a culture medium concentration of 25 mM in comparison to the control.
The European Centre for the Validation of Alternative Methods (ECVAM) declared in 2001 that the post-implantation rat whole-embryo culture (WEC) assay was a scientifically validated test, which was ready to be considered for regulatory purposes (The Use of Scientifically-Validated In Vitro Tests for Embryotoxicity, ECVAM Institute for Health & Consumer Protection, Joint Research Centre, European Commission, 2002). Im ECHA REACH guidance R.7a it is stated that the whole embryo culture showed high predictivity for certain strongly embryotoxic chemicals (which is supported by the second test item acetaldehyde in the present study) but due to the nature of the methods and limitations in their predictivity, it could be used only as supporting information along with other more reliable data to predict the developmental toxicity. In conclusion, the present study was considered relevant for assessment of developmental / teratogenic toxicity of 2,3 -butanediol.
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Study period:
- 1986
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Reason / purpose for cross-reference:
- assessment report
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Deviations:
- yes
- GLP compliance:
- not specified
- Limit test:
- no
- Specific details on test material used for the study:
- Reagent Grade, 98% minimum assay, Lot No. 714739, Fisher Scientific Co.
- Species:
- rat
- Strain:
- Long-Evans
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Blue-Spruce Farms in Altamont, NY
- Weight at study initiation: 200-300 g
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
1,3-butanediol solutions (35.30, 21.18, or 3.53% w/v) and distilled water were freshly prepared, and daily doses of 20 ml/kg were given by gavage to pregnant Long-Evans rats, based on their current bodyweights. - Analytical verification of doses or concentrations:
- no
- Details on mating procedure:
- - Impregnation procedure: cohoused
- Duration of treatment / exposure:
- from day 6 to day 15 of gestation
The presence of sperm in the vaginal smear was defined as day 0 of gestation. - Frequency of treatment:
- daily
- Dose / conc.:
- 0 mg/kg bw/day
- Remarks:
- Group I
- Dose / conc.:
- 7 060 mg/kg bw/day
- Remarks:
- Group II
- Dose / conc.:
- 4 236 mg/kg bw/day
- Remarks:
- Group III
- Dose / conc.:
- 706 mg/kg bw/day
- Remarks:
- Group IV
- No. of animals per sex per dose:
- 40 females (10 females per each group)
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: The exposure levels were chosen as fractional doses (24, 14.4, and 2.4%) of the acute LDso value for butanediol, similar to previous studies with other alcohols.
- Maternal examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: daily
DETAILED CLINICAL OBSERVATIONS: No
BODY WEIGHT: No
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): Yes
- Food consumption was monitored by daily visual inspection of ground diet (Wayne Lab Blox) remaining in calibrated metal feed cups.
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No
POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day 20
- Organs examined: total uterine weight
- Ovaries and uterine content:
- The ovaries and uterine content was examined after termination
Examinations included:
total litter weigh;, individual pup weights, crown-rump length, number of live pups, stillbirths and resorptions, implantation sites, sex distribution, and number of corpora lutea - Fetal examinations:
- - External examinations(gross malformation): Yes: [all per litter]
- Soft tissue examinations: Yes: [all per litter ]
- skeletal and cartilaginous examinations: Yes: [all per litter]
- Head examinations: No - Statistics:
- The parametric analysis of variance and Newman-Keuls posthoc analyses were used to compare maternal bodyweights, uterine weights, litter weights, pup weights, crown-rump lengths, corpora lutea, implantations, percent of males per litter, intrauterine deaths per litter, malformed pups per litter, and pup bodyweights by contiguity classification on an absolute and relative (percent of control) basis. Contingency table analyses (Chisquare and Fisher exact test) were applied to litters bearing malformed pups. Linear regression analysis of butanediol dose against pup bodyweight was performed.
- Historical control data:
- Not specified
- Clinical signs:
- no effects observed
- Dermal irritation (if dermal study):
- not examined
- Mortality:
- no mortality observed
- Body weight and weight changes:
- not examined
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- not examined
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- not examined
- Histopathological findings: neoplastic:
- not examined
- Details on results:
- Signs of mild maternal narcosis (lethargy, decreased response to light cage tap) were noted in rats of groups I1 and 111 within 1 hour of butanediol gavage. All animals appeared to be normal within 8 hours of dosing. Feed consumptions, total gestation weight gains, and maternal weight gains were similar for all groups.
- Fetal body weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Dams given high doses of the ethanol dimer butanediol had a significant (P < 0.001, two-tailed) dose-related (r -0.58) birthweight depression in their live offspring at day 20 of gestation. This significant (one-way analysis of variance; P < 0.01, F 5.52, df3) birthweight depression affected pups of group II as compared to controls (Newman-Keuls posthoc analysis; P < 0.01).
- Changes in sex ratio:
- no effects observed
- Changes in litter size and weights:
- no effects observed
- Changes in postnatal survival:
- not examined
- External malformations:
- effects observed, treatment-related
- Description (incidence and severity):
- No significant increase of malformed pups, attributable to butanediol exposure, was observed in any group. However, a number of minor, growth-related structural variations were observed in pups of group II. Runting (defined as a pup weighing less than 2.7 g) occurred in 6 of 95 group II pups (no control pups were runted).
- Skeletal malformations:
- effects observed, treatment-related
- Description (incidence and severity):
- Sternebral variations (missing, incomplete, or incompletely calcified) were noted in 15 of 95 group II pups, as compared to 7 of 112 group I pups.
- Visceral malformations:
- not examined
- Details on embryotoxic / teratogenic effects:
- No differences attributable to butanediol were detected in litter weights, crown-rump lengths, corpora lutea, implantations, litter size, sex prevalence, intrauterine deaths, malformed pups per litter, or litters with malformed pups (P > 0.05; analysis of variance with Newman-Keuls posthoc test).
In the present studies, embryotoxity (reduced birthweight) selectively affects Mo offspring exposed in utero to high levels of butanediol, and although no significant overall increase in malformations was observed, group II pups were more frequently runted and had a greater incidence of sternebral variations than controls, coincident with depressed birthweight. - Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 4 236 mg/kg bw/day
- Based on:
- test mat.
- Basis for effect level:
- fetal/pup body weight changes
- Abnormalities:
- not specified
- Key result
- Developmental effects observed:
- yes
- Lowest effective dose / conc.:
- 7 060 mg/kg bw/day
- Treatment related:
- yes
- Relation to maternal toxicity:
- developmental effects in the absence of maternal toxicity effects
- Dose response relationship:
- yes
- Relevant for humans:
- not specified
- Conclusions:
- Embryotoxity (reduced birthweight) selectively affects Mo offspring exposed in utero to high levels (4236 mg/kg and 7060 mg/kg) of butanediol, and although no significant overall increase in malformations was observed, group II pups were more frequently runted and had a greater incidence of sternebral variations than controls, coincident with depressed birthweight. Fetal bodyweight and skeletal variations (retarded ossifications) are considered to reflect the birthweight reductions and are not indicative of a teratogenic effect of butanediol.
- Executive summary:
The embryotoxic effects of high doses of the narcotizing ethanol dimer 1,3-butanediol were evaluated in pregnant Long-Evans rats during the “critical period” of organogenesis. Butanediol was given by gavage at levels of 0, 7060, 4236, or 706 mg/kg per day. Maternal sedation was observed at 7060 and 4236 mg/kg, but feed consumptions and maternal body weights were unaffected. Butanediol caused a significant, dose-dependent decrease in offspring birthweights. Embryotoxity (reduced birthweight) selectively affects Mo offspring exposed in utero to high levels (4236 mg/kg and 7060 mg/kg) of butanediol, and although no significant overall increase in malformations was observed, group II pups were more frequently runted and had a greater incidence of sternebral variations than controls, coincident with depressed birthweight. Fetal bodyweight and skeletal variations (retarded ossifications) are considered to reflect the birthweight reductions and are not indicative of a teratogenic effect of butanediol.
Referenceopen allclose all
Conducted as part of reproduction study; no definitive
dose-related teratological findings in either soft or
skeletal tissue. Fetotoxicity(e.g., delayed ossification of
sternebrae) noted at 10% and 24% doses, 5000 and 12000 mg/kg bw/d,
respectively.
Incidence of fetal skeletal abnormalities in F3B generation:
Dietary level (%) | ||||
0 | 5 | 10 | 24 | |
No. of fetuses examined | 124 | 103 | 120 | 103 |
Sternebrae | ||||
Incomplete ossification | 31 | 31 | 48* | 65* |
Scrambled | 1 | 0 | 0 | 0 |
Bipartite | 1 | 1 | 0 | 3 |
Extra | 1 | 0 | 0 | 0 |
Missing | 10 | 3 | 13 | 37** |
Ribs | ||||
More than 13 | 4 | 4 | 1 | 1 |
Vertebrae | ||||
Incomplete ossification | 4 | 1 | 1 | 2 |
Scoliosis | 1 | 0 | 0 | 0 |
Skull | ||||
Incomplete closure | 9 | 0 | 3 | 10 |
Hyoid bone | ||||
Missing | 2 | 0 | 0 | 2 |
Reduced | 0 | 0 | 0 | 1 |
*: significantly different from respective control, p </= 0.025
**: significantly different from respective control, p </= 0.01
Resorption and implantation data for F3B generation:
Mean no. of pups per litter | ||||||
Dietary level (%) | No. of pregnant females | Viable | Non-viable | Implantations (mean per dam) | Resorptions(mean per dam) | Mean fetal weight (g) |
0 | 15 | 11.9 | 0 | 12.5 | 0.6 | 3.5 |
5 | 15 | 10.1 | 0 | 10.4 | 0.3 | 4.0 |
10 | 14 | 12.1 | 0 | 12.6 | 0.5 | 4.1 |
24 | 14 | 10.9 | 0 | 11.4 | 0.5 | 3.4 |
Effects of acetaldehyde and butane-2,3-diol on 10 -day rat embryo development in vitro (WEC - Whole-Embryo Culture Assay)
Treatment | No. | Somites | Protein (µG) | DNA (µG) | No with heartbeat | Normal gross morphology (%) |
Control | 18 | 33.6 ± 0.3 | 738 ± 49 | 73 ± 4 | 18 | 18 (100) |
Acetaldehyde [µM] | ||||||
102 ± 6.7 | 17 | 33.8 ± 0.3 | 662 ± 31 | 73 ± 4 | 17 | 16 (94) |
260 ± 26.3 | 21 | 33.6 ± 0.2 | 628 ± 20 | 73 ± 4 | 21 | 19 (91) |
815 ± 24.6 | 6 | Uncountable * | 67 ± 19 * | < 5 * | 0 * | 0 (0) * |
2,3-butanediol [µM] | ||||||
25 | 12 | 33.6 ± 0.3 | 698 ± 24 | 78 ± 3 | 12 | 12 (100) |
* P < 0.5 compared with control values.
Effect on developmental toxicity: via oral route
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 2 500 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- sufficient for evaluation
Effect on developmental toxicity: via inhalation route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via dermal route
- Endpoint conclusion:
- no study available
Additional information
No key study is available on developmental / teratogenic toxicity for the target substance. However, adequate and reliable data are reported here for a structural analogue (source substance 1,3 -butanediol). Furthermore, a supporting study is available investigate the effects of 2,3-butanediol (isomer mix) on rat embryos developing in vitro. Please also refer to the read-across justification document.
No teratogenic effects were observed in the key study on developmental toxicity (Hess et al. 1981). Fetotoxic effects (missing sternebrae, incomplete ossification of sternebrae) were recorded at concentrations of 10% and 24% of butane-1,3-diol (CAS 107-88-0) in the diet (5000 and 12000 mg/kg bw/day) in the study. The NOAEL was 5% 1,3 -butanediol in the diet (2500 mg/kg bw/day). In a nearly guideline conform test a NOAEL for fetotoxic effects (decreased birthweight) of 4236 mg/kg bw/day was observed (Mankes et al., 1986). Additionally, in this study a number of minor, growth-related structural variations were observed in pups, which were in accordance with the findings of the key study.
The effects observed in fetuses, especially the effects on sternebrae, are regarded as substance related and adverse. However, as these effects were only observed at doses which clearly exceed the limit values recommended in current guidelines. Therefore it is concluded that no classification for effects on development is required.
Priscott (1984) investigated the effects of acetaldehyde and 2,3-butanediol (isomer mix) on rat embryos developing in vitro (supporting study). The study used rat post-implantation embryo culture model (WEC - Whole-Embryo Culture Assay). Embryo toxicity of 2,3-butanediol were examined in cultured 10-day Albino Wistar rat embryos over a 2-day period (n=12). After exposure to 25 mM (2253 mg/L) of 2,3-butanediol, no differences in embryonic protein, DNA, somite development, gross morphology and viability were observed. 2,3 -butanediol had no significant effect in any of the examined parameter at a culture medium concentration of 25 mM in comparison to the control. The NOAEC of 2253 mg/L (ppm) of the supporting study can be expressed as 0.23% exposure solution of 2,3 -butanediol.
In ECHA REACH guidance R.7a it is stated that the whole embryo culture showed high predictivity for certain strongly embryotoxic chemicals (which was supported by the second test item acetaldehyde examined in the same study at far lower concentration) but due to the nature of the methods and limitations in their predictivity, it could be used only as supporting information along with other more reliable data to predict the developmental toxicity. In conclusion, the present study was considered relevant for assessment of developmental / teratogenic toxicity of 2,3 -butanediol.
Mode of Action Analysis / Human Relevance Framework
In the absence of information on species specific effects or metabolism the results are regarded as relevant for humans.
Justification for classification or non-classification
Classification, Labelling, and Packaging Regulation (EC) No 1272/2008
The available experimental test data are reliable and suitable for classification purposes under Regulation (EC) No 1272/2008. Based on available data on reproductive toxicity the test item does not require classification according to Regulation (EC) No 1272/2008 (CLP), as amended for the eighteenth time in Regulation (EU) 2022/692.
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.